Neuronetics reports preliminary Q4 revenue over $20M, record treatment session revenue

Neuronetics, Inc.

2023-FY EPS reported -$1.05 revenue$71,348,000

Preliminary Q4 2023 total revenue >$20M (guidance $19-21M); U.S. NeuroStar system revenue ~$4.5M on 59 system shipments.
U.S. Treatment Session revenue >$14.5M (company record, +20% YoY); local consumable revenue +33% YoY.
Generated positive cash flow >$1M in Q4; ended 2023 with cash and equivalents ~$59M.
Full year 2023 preliminary revenue >$71M (guidance $70-72M); momentum cited across key customer segments.
Next phase of Better Me Guarantee Provider pilot to launch Jan 22, 2024 with ~100 sites; over 275 sites eligible later in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Neuronetics, Inc. reported the three months ended December 31, 2023 results: revenue over $20 million.

Period: the three months ended December 31, 2023
Revenue: over $20 million
Result: preliminary results

Exact text from the filing

Preliminary unaudited total revenue is expected to be over $20 million as compared to previously stated guidance of $19.0 to $21.0 million.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Neuronetics, Inc. reported the twelve months ended December 31, 2023 results: revenue over $71 million.

Period: the twelve months ended December 31, 2023
Revenue: over $71 million
Result: preliminary results

Exact text from the filing

Preliminary unaudited total revenue is expected to be over $71 million as compared to previously stated guidance of $70.0 to $72.0 million.

View on SEC.gov

Browse all earnings releases →

Neuronetics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-003966

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.